1. Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, NY;
2. Unit of Medicine and Clinical Immunology, Istituto di Ricovero e Cura a Carattere Scientifico San Raffaele Scientific Institute, Milan, Italy;
3. Developmental Therapeutics Unit, Memorial Sloan-Kettering Cancer Center, New York, NY;
4. Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), The University of Texas MD Anderson Cancer Center, Houston, TX;
5. Medical Genetics Branch, Office of the Clinical Director, National Human Genome Research Institute, and Hematology Section, Department of Laboratory Medicine, National Institutes of Health, Bethesda, MD;
6. Department of Oncology, Istituto di Ricovero e Cura a Carattere Scientifico San Raffaele Scientific Institute, Milan, Italy;
7. Human Oncology and Pathogenesis Program and Leukemia Service, Memorial Sloan Kettering Cancer Center, New York, NY;
8. Division of Hematology/Oncology, Columbia University Medical Center, New York, NY;
9. Division of Nephrology, The Johns Hopkins University School of Medicine, Baltimore, MD
10. Texas Children's Cancer and Hematology Centers, Baylor College of Medicine, Houston, TX;
11. University Hospital of Parma, Parma, Italy;
12. Mayo Clinic-Arizona, Laboratory Medicine and Pathology, Scottsdale, AZ; and
13. Department of Internal Medicine, Assistance Publique – Hôpitaux de Paris, French Reference Center for Auto-Immune Diseases, Hôpital Pitié-Salpêtrière, Paris, France